Together, these approaches revealed that VDR signaling qualitatively and quantitatively differed between AA and EA cells, and that BAZ1A expression in AA prostate cancer regulated the capacity of the VDR to control immunomodulatory and circadian signaling. This evidence concerns the gene BAZ1A and Familial prostate cancer.